Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sarepta (SRPT) Bullish View Reiterated at Credit Suisse at EXONDYS51 Gains Momentum
April 28, 2017 6:45 AM EDTCredit Suisse analyst Alethia Young reiterated an Outperform rating and $64 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company raised guidance to $95M from $80M as the launch continues to look "highly encouraging"
The firm's new 2017 estimate is $103M, up... More
Sarepta Therapeutics (SRPT) Misses Q1 EPS by 24c, Revenue Beats
April 27, 2017 4:11 PM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.60), $0.24 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $13.86 million.
Company anticipates net revenues for the year will exceed $95 million
(Street sees FY rev... More
